Maria Koukoulaki

Maria Koukoulaki

Auto-generated profile, based on publicly available information

Maria Koukoulaki

Center for Nephrology “G. Papadakis”, General Hospital of Nikaia–Piraeus “Agios Panteleimon”, Piraeus, Greece

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2021 in American Journal of Nephrology
Verified
Journal Article
Closed access
PDF file
PTPanagiotis Theofilis
Panagiotis Theofilis
AVAikaterini Vordoni
Aikaterini Vordoni
MKMaria Koukoulaki
Maria Koukoulaki
GVGeorgios Vlachopanos
Georgios Vlachopanos
RKRigas G Kalaitzidis
Rigas G Kalaitzidis
Background: Chronic kidney disease (CKD) is an increasingly prevalent disease state met with great morbidity and mortality primarily resulting from the high incidence of adverse cardiovascular outcomes. Therapeutic strategies in this patient population aim at controlling modifiable cardiovascular risk factors, including dyslipidemia. Summary: In this review article, we first provide the latest pathophysiologic evidence regarding the altered dyslipidemia pattern in CKD, followed by its contemporary management according to the latest guidelines. Moreover, we present the current progress regarding the emerging therapeutic strategies. Key Messages: The presence of renal impairment leads to alterations in cholesterol structure, metabolism, and reverse transport paired with increased oxidative stress. Statins remain the cornerstone of dyslipidemia management in patients with kidney dysfunction who are at risk for cardiovascular events. However, their efficacy is debatable in end-stage renal disease under renal replacement therapy. Therefore, novel treatment approaches aiming at hypertriglyceridemia, proprotein convertase subtilisin/kexin type 9, and lipoprotein(a) are under rigorous investigation while the research of gut microbiome might provide additional mechanistic and therapeutic insight.

14 February 2022 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
PTPanagiotis Theofilis
Panagiotis Theofilis
AVAikaterini Vordoni
Aikaterini Vordoni
MKMaria Koukoulaki
Maria Koukoulaki
GVGeorgios Vlachopanos
Georgios Vlachopanos
RKRigas G Kalaitzidis
Rigas G Kalaitzidis

7 June 2005 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
IKIoannis S. Kaskarelis
Ioannis S. Kaskarelis
MKMaria Koukoulaki
Maria Koukoulaki
ILIoannis Lappas
Ioannis Lappas
FKFani Karkatzia
Fani Karkatzia
NDNikitas Dimopoulos
Nikitas Dimopoulos
SDSpiros Drakopoulos
Spiros Drakopoulos

1 February 2011 in Clinical Nephrology
Verified
Journal Article
Closed access
ESE. Savvidaki
E. Savvidaki
MKM. Koukoulaki
M. Koukoulaki
ABA. Benou
A. Benou
MRM. Roumeliotou
M. Roumeliotou
CFCOSTAS FOURTOUNAS
COSTAS FOURTOUNAS
DGD. Goumenos
D. Goumenos
Ezetimibe is a hypolipidemic agent acting via inhibition of cholesterol absorption from the small intestine. The effectiveness and safety of long-term administration of ezetimibe was evaluated in renal allograft recipients with persistent hyperlipidemia. 67 renal allograft recipients with post-transplantation hyperlipidemia resistant to statins were included in the study; 11 were treated with ezetimibe (10 mg/day) alone and 56 with ezetimibe and statin. The effectiveness of ezetimibe was assessed by determination of total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C) and triglycerides (TR). Its safety was determined by liver enzymes (ALT, AST), LDH, CPK, serum creatinine and blood levels of immunosuppressive drugs (cyclosporine, tacrolimus, everolimus, sirolimus) over the follow-up period of 18±6 months. A significant reduction of TC and LDL-C blood levels by 25% and 34% respectively, was observed during the first month of treatment with ezetimibe (p<0.001). This reduction was maintained for the whole period of ezetimibe administration. Renal function remained stable over the follow-up period, while no changes of the blood levels of immunosuppressive drugs were observed. Liver enzymes, LDH and CPK remained normal in all patients except for one diabetic patient who developed rhabdomyolysis. Apart from gastrointestinal symptoms in 2 patients, no other side effects were observed. Combination of ezetimibe with statins represents an effective and safe regimen for treatment of persistent hyperlipidemia in renal allograft recipients.

1 November 2014 in Transplantation Proceedings
Verified
Journal Article
Closed access
MKM. Koukoulaki
M. Koukoulaki
VKV. Kitsiou
V. Kitsiou
ABA. Balaska
A. Balaska
DPD. Pistolas
D. Pistolas
ILI. Loukopoulos
I. Loukopoulos
EHE. Hadjiyannakis
E. Hadjiyannakis